Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Pharmaceutical Investing
Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease Life Science Investing
FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat Pharmaceutical Investing
Clearside Biomedical Submits New Drug Application for XIPERE for the Treatment of Macular Edema Associated with Uveitis Pharmaceutical Investing
G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib Pharmaceutical Investing
